Registry update — unassessed
A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study. Extension Protocol
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
OTHERMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 21, 2026 · Discovered: Sep 23, 2026 · Assessed: — · Research update
What it does not prove
- This is a protocol description rather than a results report; no efficacy or safety data are presented. Sample size and actual effect sizes are not reported, preventing assessment of statistical power or clinical significance. The study design and outcomes are stated as planned objectives rather than demonstrated findings.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- Haukeland University Hospital
- Published
- Sep 21, 2026
Sources
Primary source
- Haukeland University Hospital ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years.
In the NO-ALS extension study the investigators will follow the patients who completed the original NO-ALS study.
Objectives are to evaluate adverse events and give patients possibility of compassionate use, and secondarily to see if the combination of NR and pterostilbene (EH301) will decrease progression of motor symptoms and loss of vital capacity, and increase survival time in patients with ALS.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.